Scott Abrams Scott Abrams, PhD

Scott Abrams

PhD

Special Interests:

Defining molecular mechanisms by which lymphocytes kill tumor cells in vivo Identifying tumor escape mechanisms, with emphasis on how the neoplastic process promotes immune suppression Developing novel combination therapies to augment anti-cancer responses

About Me

Biography:

Dr. Scott Abrams joined the Faculty of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2008 and, in 2013, was promoted to Professor of Oncology and Member in the Department of Immunology. He holds a joint appointment as Research Professor on the Graduate Faculty at the State University of New York at Buffalo. In 2014, Dr. Abrams was reappointed to the UB Graduate Faculty with Distinction.  From 2013 to early 2019, he served as Director of Graduate Studies for the Immunology Graduate Program at Roswell Park during which he received two awards in graduate education and mentoring.  Also, in 2018, he received the Roswell Pride in Member Ingenuity (RPMI) Award. In early 2019, Dr. Abrams was appointed as Co-Leader of the Tumor Immunology and Immunotherapy Program in the Cancer Center.

Dr. Abrams came to Roswell Park from the Laboratory of Tumor Immunology and Biology, National Cancer Institute (NCI), National Institutes of Health (NIH), in Bethesda, MD, where he served as Principal Investigator. He has been honored by the NCI/NIH with five consecutive Performance Awards from 2003–2007, and was the recipient of six NIH Federal Technology Transfer Awards for the discovery of human T lymphocyte peptide epitopes reflecting ras codon 12 mutations. The identification of such mutated ras peptide sequences has also culminated in patent approval in both Europe and the U.S.

As a tumor immunologist, his research interests focus on understanding mechanisms of tumor escape and immune suppression. Currently, Dr. Abrams serves on several external grant review panels. He has authored or co-authored more than 130 journal articles, reviews and book chapters, and has received numerous national and international invitations to speak.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Department of Immunology
  • Co-Leader, Tumor Immunology and Immunotherapy Program

Background

Education and Training:

  • PhD (Microbiology and Immunology) Indiana University School of Medicine, Indianapolis, IN

Professional Memberships:

  • American Association for Cancer Research
  • American Association of Immunologists
  • Sigma Xi Society
  • Society for Immunotherapy of Cancer

Research

Research Overview:

Dr. Abrams' research focus is in tumor immunology; specifically, how solid tumors impair the normal process of myeloid cell production leading to the generation of myeloid-derived suppressor cells (MDSCs) which potently suppress antitumor immunity. Although much attention in this field has been devoted to unraveling mechanisms by which MDSCs mediate such immune suppression, a larger gap has remained in the understanding of the molecular or transcriptional mechanisms that initiate their development. Thus, over the past several years, the Abrams laboratory has been testing the central hypothesis that tumor-induced downregulation of interferon regulatory factor-8 (IRF8) compromises normal myelopoiesis, resulting in myeloproliferative phenotypes heavily characteristic of MDSCs. Emphasis has been placed on IRF8, since IRF8 is well-recognized as a key transcriptional player in normal myeloid cell development and differentiation.

Now published in a series of research articles, including The Journal of Clinical Investigation, his work defines a new paradigm in MDSC biology reflecting early transcriptional cues that profoundly affect MDSC development in neoplastic disease, such as breast cancer. The Abrams Lab has also engaged in a number of collaborations with other RPCI investigators reflecting shared research interests. For example, through the newly awarded RPCI-UPCI Ovarian Cancer SPORE, Dr. Abrams works with Drs. Odunsi and Moysich to study the association between MDSCs and ovarian cancer prognosis. The long-term goals of his research program are to advance an understanding of how the neoplastic process impairs the host immune response, thereby providing new insights into the design of strategies that can more effectively battle this extraordinarily complex family of diseases.


Publications

Full Publications list on PubMed

Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C Jr, Nam B, Bennett J, Masters G, Guarino M, Kumar A, Nefedova Y, Vonderheide RH, Languino LR, Abrams SI, Gabrilovich DI. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. J Exp Med. 2019 Sep 2;216(9):2150-2169. doi: 10.1084/jem.20181952. Epub 2019 Jun 25. PubMed PMID: 31239386; PubMed Central PMCID: PMC6719429.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0. PubMed PMID: 31221219; PubMed Central PMCID: PMC6585080.

Twum DY, Colligan SH, Hoffend NC, Katsuta E, Cortes Gomez E, Hensen ML, Seshadri M, Nemeth MJ, Abrams SI. IFN regulatory factor-8 expression in macrophages governs an antimetastatic program. JCI Insight. 2019 Feb 7;4(3). doi: 10.1172/jci.insight.124267. [Epub ahead of print] PubMed PMID: 30728331; PubMed Central PMCID: PMC6413790.

Burkard-Mandel L, O'Neill R, Colligan S, Seshadri M, Abrams SI. Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology. 2018;7(5):e1419115. doi: 10.1080/2162402X.2017.1419115. eCollection 2018. PubMed PMID: 29721367; PubMed Central PMCID: PMC5927533.

Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A, Cortes Gomez E, Wang J, Nemeth MJ, Abrams SI. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production. J Immunol. 2017 May 15;198(10):4129-4139. doi: 10.4049/jimmunol.1601722. Epub 2017 Mar 29. PubMed PMID: 28356386; PubMed Central PMCID: PMC5450940.